Cardiotoxicity

Drug Prevents Heart Damage in Pediatric Patients Receiving Chemotherapy

Drug Prevents Heart Damage in Pediatric Patients Receiving Chemotherapy

By

Dexrazoxane has cardioprotective properties that can prevent long-term cardiotoxicity in pediatric patients receiving chemotherapy, according to a review of the medical literature on cardiotoxic effects of anthracycline treatment.

Trastuzumab-related Cardiotoxicity Lower Among Taiwanese Patients

Trastuzumab-related Cardiotoxicity Lower Among Taiwanese Patients

By

Trastuzumab-related cardiotoxicity was far lower in Taiwanese women with breast cancer compared with previously published results, according to recent study data.

Breast Cancer Therapy and Cardiotoxicity Risk in Older Women

Breast Cancer Therapy and Cardiotoxicity Risk in Older Women

By

A study examined the relation between various forms of breast cancer therapies and risk of congestive heart failure.

Patients with BRCA 1/2 mutations not at increased risk for anthracycline-induced cardiotoxicity

Patients with BRCA 1/2 mutations not at increased risk for anthracycline-induced cardiotoxicity

Breast cancer patients with BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs